Company news
Pacira Biosciences, Inc. (NASDAQ:PCRX) news
Every Pacira Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pacira BioSciences Reports Second Quarter 2026 Financial Results
August 4, 2026
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
July 28, 2026
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
July 27, 2026
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
July 22, 2026
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
June 30, 2026
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
June 9, 2026
Egan-Jones Recommends Pacira Shareholders Support All Management Nominees
June 5, 2026
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead o...
June 4, 2026
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
June 1, 2026
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DES...
May 28, 2026
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
May 27, 2026
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients ...
May 27, 2026
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
May 26, 2026
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
May 21, 2026
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
May 20, 2026
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockho...
May 20, 2026
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card...
May 13, 2026
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
May 13, 2026
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
May 12, 2026
Pacira BioSciences Mails Letter to Stockholders
May 5, 2026
Pacira BioSciences Reports First Quarter 2026 Financial Results
April 30, 2026
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
April 28, 2026
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
April 27, 2026
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
April 16, 2026
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
April 13, 2026
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
March 30, 2026
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
March 11, 2026
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
March 4, 2026
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
March 2, 2026
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
February 26, 2026
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
February 12, 2026
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
February 12, 2026
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
January 28, 2026
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
January 13, 2026
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
January 8, 2026
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
January 7, 2026
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Mee...
December 30, 2025
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
December 18, 2025
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 3, 2025
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With i...
December 2, 2025
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
November 26, 2025
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
November 11, 2025
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
November 10, 2025
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
November 6, 2025
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment o...
November 5, 2025
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
November 4, 2025
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
October 30, 2025
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients wit...
October 28, 2025
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
October 27, 2025